Overview

GW873140 In Combination With Kaletra In HIV Infected Subjects

Status:
Terminated
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Kaletra in HIV infected, untreated subjects.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
ViiV Healthcare
Treatments:
Aplaviroc
Lopinavir
Ritonavir